Drug Database
Back to search

Finland· FI-REL-REL5801

Velosef

A cefradine product, registered in Finland by Bristol-Myers Squibb GmbH. The same ATC class is registered in 2 of our 19 countries.

ATC J01DB09

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVelosefATCJ01DB09REGISTER NO.FI-REL-REL5801PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about VelosefAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cefradine is registered in 2 of 19 countries.

Countries holding a registration under ATC J01DB09 (cefradine), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 1 of them publish a price we can compare per daily dose
Search cefradine products by name

Cefradine · ATC J01DB09

2 / 19 countries

  • Finlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Manufacturer
Bristol-Myers Squibb GmbH
Country
Finland (FI)
ATC code
J01DB09
ATC class
Cefradine
Defined daily dose
2 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

20 interactions on record for cefradine.

Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cefradine against other medicinesHow interaction checks work

Cefradine · interactions on record

20 records

  • 20 moderate

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • KanamycinA07AA08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under J01DB09

Cefradine, as other registers publish it.

All cefradine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/de48b961-6165-4484-8b47-e58ce5cde946
GET /v1/drugs/de48b961-6165-4484-8b47-e58ce5cde946?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "2",
  "form": "kapseli",
  "route": null,
  "ddd_unit": "g",
  "strength": "500 mg",
  "atc_label": "kefradiini",
  "ma_number": "7201",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL5801",
  "authorised_at": "1976-03-10"
}
API referenceMCP serverPlans

See everything about cefradine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console